Neurosense Confirms Favorable Safety And Tolerability Of Primec In An Alzheimer's Phase 2 Study
Dec 22 (Reuters) - Neurosense Therapeutics Ltd NRSN.O:
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.